Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Blinded, Parallel-Controlled Phase I/III Clinical Trial to Evaluate the Safety and Immunogenicity of Adsorbed Tetanus Vaccine in Healthy Individuals Aged 18-43 Years

NCT07740733 is registered in ClinicalTrials.gov with Beijing Minhai Biotechnology Co., Ltd as lead sponsor.

NCT NCT07740733
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07740733 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Blinded, Parallel-Controlled Phase I/III Clinical Trial to Evaluate the Safety and Immunogenicity of Adsorbed Tetanus Vaccine in Healthy Individuals Aged 18-43 Years
Lead sponsor
Beijing Minhai Biotechnology Co., Ltd
Phase
Phase 3
Overall status
Completed
Start date
February 29, 2024
Completion date
December 23, 2024
Enrollment
1,240 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

tetanus, tetanus vaccine